Angela Genge, MD, specializes in clinical trial design and development for rare neurological conditions with a particular emphasis on ALS/MND. She has served as the executive director of the clinical research unit at the Montreal Neurological Institute and Hospital since 2004 and director of its ALS clinic since 1998. Under her direction, the clinical research unit has evolved to contain a first-of-its-kind Phase 1 unit dedicated to neurological diseases. The unit also has an ALS Global Center of Excellence and the Excellence in Rare Neurological Disease Clinical Trials Effort (ERADICATE) Network, both of which fuel the drug discovery pipeline and accelerate the development of new therapies for rare and terminal neurological diseases. In addition to serving as QurAlis’ chief medical officer, Angela serves as the global principal investigator for AL-S Pharma, is scientific director of CATALIS Quebec, as well as sits on numerous advisory boards and data and safety monitoring boards. She previously served a distinguished clinical investigator for Novartis Global.

Throughout her career, Angela has received numerous awards in recognition of her exceptional care and management of ALS studies and patients including the 2018 Forbes Norris Award, the DIVA of Distinction Award, the YMCA Woman of the Year Award, and the Governor General Diamond Jubilee Award. She completed her medical degree at Memorial University of Newfoundland and earned a B.Sc. from Dalhousie University. A fellow of the Royal College of Physicians and Surgeons (Canada), Angela completed her Canadian and American certifications in internal medicine and neurology at McGill University prior to completing a fellowship in neuromuscular diseases at the Montreal Neurological Institute.